Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Alabama at Birmingham Genentech |
---|---|
Information provided by: | University of Alabama at Birmingham |
ClinicalTrials.gov Identifier: | NCT00334945 |
The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth. It is well known that growth hormone treatment improves bone density and bone mineral content. The amount of phosphorus is maintained by the kidneys. Fibroblast 23 has recently been recognized to help kidneys control phosphate levels.
Condition |
---|
Growth Disorders |
Study Type: | Observational |
Study Design: | Longitudinal, Case Control, Prospective Study |
Official Title: | Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23 (a Known Phosphaturic Agent) |
Ages Eligible for Study: | 3 Years to 14 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Tammi L Skelton, RN, BSN | 205-939-9107 | tskelton@peds.uab.edu |
United States, Alabama | |
Children's Hospital of Alabama | Recruiting |
Birmingham, Alabama, United States, 35233 |
Principal Investigator: | Kenneth L McCormick, MD | University of Alabama at Birmingham |
Study ID Numbers: | X041104010, X3395n |
Study First Received: | June 7, 2006 |
Last Updated: | April 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00334945 |
Health Authority: | United States: Institutional Review Board |
Fibroblast Growth Factors Bone development |
Growth Disorders |
Pathologic Processes |